These findings are suggestive of a founder effect.
A founder effect can occur when a small group of people from one population separate and form a new population. An allele that had a rare frequency in the parent population may then have a higher frequency in the new population simply because one or more of the founders happened to carry the rare allele. If the new population remains isolated as it expands, as has been the case in parts of Quebec, and especially if there is inbreeding, as was the case in this patient's family, the founder allele is able to become homozygous, thus causing autosomal recessive diseases such as AID deficiency. The R112C mutation has never been reported in France, the country of the Quebec founders. This is not surprising because the mutation may have a low frequency in France, and in the absence of inbreeding, it may never manifest as disease. However, one cannot exclude the possibility that the R112C mutation did not exist in the Quebec founders but in fact occurred afterwards. Regardless, genotyping of polymorphisms surrounding R112C has demonstrated a single haplotype, and has thus confirmed that the mutation originated from a single individual. In 55 non-French Canadians with AID deficiency, this mutation was found only once [1] [2] [3] : a Japanese patient was heterozygous for R112C, the other AID gene having a premature stop codon. It is interesting to contemplate whether this patient had a French or French-Canadian ancestor or whether the Japanese mutation arose independently.
In summary, this case illustrates the typical clinical manifestations of hyper-IgM syndrome due to AID deficiency, which differ significantly from those of hyper-IgM syndrome due to CD154 deficiency: normal growth, the presence of lymphadenopathy, infections only of bacterial origin, and the lack of cytopenias. Our patient's AID mutation proved to be identical to that found in all other French Canadians with this disease, illustrating a mutation that is identical by descent. 
